利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

33 条记录 (耗时 0.017 秒)

    The CD40CR receptor and ligands therefor
    3.
    发明公开
    The CD40CR receptor and ligands therefor 无效
    CD40CR-Rezeptor und Ligandendafür。

    公开(公告)号：EP0555880A2

    公开(公告)日：1993-08-18

    申请号：EP93102279.2

    申请日：1993-02-12

    申请人： Bristol-Myers Squibb Company ,  TRUSTEES OF DARTMOUTH COLLEGE ,  THE GENERAL HOSPITAL CORPORATION

    发明人： Aruffo, Alejandro A. ,  Ledbetter, Jeffrey A. ,  Noell, Randolph ,  Stamenkovic, Ivan

    IPC分类号： C07K15/00 ,  C12P21/08 ,  A61K37/02 ,  A61K39/395

    CPC分类号： C07K16/2875 ,  A61K38/00 ,  A61K2039/505 ,  C07K14/70575 ,  C07K2317/73 ,  C07K2317/76 ,  Y10S514/885 ,  Y10S530/866 ,  Y10S530/868

    摘要： The present invention relates to a counter-receptor, termed CD40CR, for the CD40 B-cell antigen, and to soluble ligands for this receptor, including fusion molecules comprising at least a portion of CD40 protein. It is based, at least in part, on the discovery that a soluble CD40/immunoglobulin fusion protein was able to inhibit helper T-cell mediated B-cell activation by binding to a novel 39 kD protein receptor on helper T-cell membranes. The present invention provides for a substantially purified CD40CR receptor; for soluble ligands of CD40CR, including antibodies as well as fusion molecules comprising at least a portion of CD40 protein; and for methods of controlling B-cell activation which may be especially useful in the treatment of allergy or autoimmune disease.

    摘要翻译： 本发明涉及用于CD40B细胞抗原的称为CD40CR的反受体，以及该受体的可溶性配体，包括包含至少一部分CD40蛋白的融合分子。 至少部分地基于这样的发现：可溶性CD40 /免疫球蛋白融合蛋白能够通过结合辅助T细胞膜上的新型39kD蛋白受体来抑制辅助T细胞介导的B细胞活化。 本发明提供了基本纯化的CD40CR受体; 对于CD40CR的可溶性配体，包括抗体以及包含至少一部分CD40蛋白的融合分子; 以及用于控制B细胞活化的方法，其可能特别可用于治疗过敏或自身免疫性疾病。

    Tyrosine phosphorylation in protozoa
    8.
    发明公开
    Tyrosine phosphorylation in protozoa 失效
    在PROTOZOA中的酪氨酸磷酸化

    公开(公告)号：EP0507256A3

    公开(公告)日：1993-06-16

    申请号：EP92105547.1

    申请日：1992-03-31

    申请人： Bristol-Myers Squibb Company ,  SEATTLE BIOMEDICAL RESEARCH INSTITUTE

    发明人： Parsons, Marilyn ,  Ledbetter, Jeffrey A. ,  Schieven, Gary L.

    IPC分类号： A61K33/00 ,  A61K31/35 ,  A61K31/275

    CPC分类号： A61K31/35 ,  A61K31/275 ,  A61K33/00 ,  Y02A50/409 ,  Y02A50/411

    摘要： A method for the treatment of microbial-induced disorders such as the protozoa-based diseases malaria and leishmania is described in which the phosphorylation of tyrosine residues in proteins is modulated. Specific phosphorylation of trypanosomal proteins, in T. brucei , is disclosed. Tyrosine kinase and tyrosine phosphatase inhibitors are disclosed for administration to patients in the treatment method of the described invention.

    摘要翻译： 描述了一种用于治疗微生物诱导的疾病如原虫基疾病疟疾和利什曼原虫的方法，其中调节蛋白质中酪氨酸残基的磷酸化。 披露了布鲁斯布鲁氏菌中锥虫体蛋白的特异性磷酸化。 公开了酪氨酸激酶和酪氨酸磷酸酶抑制剂用于给予本发明治疗方法中的患者。

    Antibodies that bind the CD40CR receptor
    9.
    发明公开
    Antibodies that bind the CD40CR receptor 失效
    Der CD40CR Rezeptor und Ligandendafür

    公开(公告)号：EP1489099A2

    公开(公告)日：2004-12-22

    申请号：EP04012091.7

    申请日：1993-02-12

    申请人： Bristol-Myers Squibb Company ,  Trustees of Dartmouth College, d/b/a Darthmouth College of the State of New Hampshire ,  The General Hospital Corporation d/b/a Massachusetts General Hospital a corporation of Massachusetts

    发明人： Aruffo, Alejandro A. ,  Ledbetter, Jeffrey A. ,  Noell, Randolph ,  Stamenkovic, Ivan

    IPC分类号： C07K16/28 ,  A61K39/395 ,  A61P37/06 ,  A61P37/08 ,  A61P31/12 ,  A61P31/18 ,  C07K16/46

    CPC分类号： C07K16/2875 ,  A61K38/00 ,  A61K2039/505 ,  C07K14/70575 ,  C07K2317/73 ,  C07K2317/76 ,  Y10S514/885 ,  Y10S530/866 ,  Y10S530/868

    摘要： The present invention relates to an antibody that binds an antigen that:

    (a) is present on activated but not resting helper T-cells;
    (b) has the same molecular weight as a protein precipitated by a CD40-immunoglobulin (CD40-Ig) fusion protein, the CD40-Ig comprising the extracellular domain of a CD40 protein having the amino acid sequence of SEQ ID NO:2 and an extracellular domain at the site of fusion having the amino acid sequence of SEQ ID NO:3; and
    (c) is pre-cleared by precipitation with the CD40-Ig;
       wherein the antibody is capable of blocking binding of the CD40-Ig to activated helper T-cells and is capable of inhibiting helper T-cell induction of B-cell activation.
    The present invention also relates to pharmaceutical compositions comprising said antibody and the use of said antibody for therapeutic purposes, e. g. for inhibiting immunoglobulin production, inhibiting activation of B-cells and for treating disorders associated with B-cell activation, allergy, e. g.-anaphylaxis, autoimmune conditions, e. g. drug-induced lupus, systemic lupus erythematosus, adult rheumatoid arthritis, juvenile rheumatoid arthritis, scleroderma or Sjogren's syndrome, or viral diseases that involve B-cells, e. g. Epstein-Barr infection or retroviral infections such as infections with the human immunodeficiency virus.

    摘要翻译： 本发明涉及结合抗原的抗体：（a）存在于活化而不是休息的辅助性T细胞上; （b）具有与由CD40-免疫球蛋白（CD40-Ig）融合蛋白沉淀的蛋白质相同的分子量，CD40-Ig包含具有SEQ ID NO：2的氨基酸序列的CD40蛋白的细胞外结构域和 在具有SEQ ID NO：3的氨基酸序列的融合位点处的细胞外结构域; 和（c）用CD40-Ig沉淀预先清除; 其中抗体能够阻断CD40-Ig与活化的辅助性T细胞的结合，并且能够抑制辅助T细胞诱导B细胞活化。 本发明还涉及包含所述抗体和所述抗体用于治疗目的的用途的药物组合物， G。 用于抑制免疫球蛋白产生，抑制B细胞的活化和用于治疗与B细胞活化相关的疾病，过敏， 过敏反应，自身免疫病症， G。 药物诱发的狼疮，系统性红斑狼疮，成人类风湿关节炎，幼年类风湿关节炎，硬皮病或干燥综合征，或涉及B细胞的病毒性疾病， G。 爱泼斯坦 - 巴尔病毒感染或逆转录病毒感染，如人类免疫缺陷病毒感染。